Compare Stocks

→ Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$10.43 +4.3%	$14.56	$7.40 ▼ $29.70	$216.42M	0.89	322,399 shs	900,531 shs
GRNA GreenLight Biosciences	$0.30	$0.30	$0.18 ▼ $5.90	$45.43M	1.44	486,986 shs	732 shs
JNCE Jounce Therapeutics	$1.88 -2.6%	$1.89	$0.58 ▼ $5.87	$98.94M	0.75	2.46 million shs	11.60 million shs
TIL Instil Bio	$11.30 +0.7%	$11.28	$6.07 ▼ $14.00	$73.45M	1.17	9,744 shs	12,339 shs

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	+4.30%	+13.49%	-21.87%	-26.55%	+35.45%
GRNA GreenLight Biosciences	0.00%	0.00%	0.00%	0.00%	+13.32%
JNCE Jounce Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
TIL Instil Bio	+0.71%	+6.60%	+2.54%	-3.75%	-12.32%

Automatic Income (from home) (Ad)

For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year.

Just click here now to watch my presentation for free.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	3.8008 of 5 stars	3.5	1.0	0.0	4.8	2.5	2.5	0.0
GRNA GreenLight Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	3.232 of 5 stars	3.3	3.0	0.0	0.0	3.9	3.3	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	3.00	Buy	$29.00	178.04% Upside
GRNA GreenLight Biosciences	N/A	N/A	N/A	N/A
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A
TIL Instil Bio	2.67	Moderate Buy	$36.00	218.58% Upside

Current Analyst Ratings

Latest JNCE, ADVM, GRNA, and TIL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2024	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
4/29/2024	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $22.00
4/12/2024	TIL Instil Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
3/25/2024	TIL Instil Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
3/19/2024	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
2/6/2024	ADVM Adverum Biotechnologies	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $40.00

(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$3.60M	60.12	N/A	N/A	$8.26 per share	1.26
GRNA GreenLight Biosciences	$10.20M	4.45	N/A	N/A	$0.32 per share	0.94
JNCE Jounce Therapeutics	$82M	1.21	N/A	N/A	$3.54 per share	0.53
TIL Instil Bio	N/A	N/A	N/A	N/A	$34.72 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$117.17M	-$11.60	N/A	N/A	N/A	N/A	-98.65%	-52.85%	5/9/2024 (Estimated)
GRNA GreenLight Biosciences	-$167.05M	-$1.14	N/A	∞	N/A	-1,521.00%	-374.26%	-122.78%	N/A
JNCE Jounce Therapeutics	-$50.92M	-$2.56	N/A	N/A	N/A	N/A	-30.90%	-26.31%	N/A
TIL Instil Bio	-$156.09M	-$23.99	N/A	N/A	N/A	N/A	-58.49%	-41.58%	5/9/2024 (Estimated)

Latest JNCE, ADVM, GRNA, and TIL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/21/2024	Q4 2023	TIL Instil Bio	N/A	-$1.99	-$1.99	-$1.99	N/A	N/A
3/18/2024	Q4 2023	ADVM Adverum Biotechnologies	-$2.80	-$2.30	+$0.50	-$2.30	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
GRNA GreenLight Biosciences	N/A	N/A	N/A	N/A	N/A
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A
TIL Instil Bio	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	4.13	4.13
GRNA GreenLight Biosciences	0.49	1.21	1.21
JNCE Jounce Therapeutics	N/A	8.37	8.37
TIL Instil Bio	0.36	15.23	15.22

Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
GRNA GreenLight Biosciences	24.41%
JNCE Jounce Therapeutics	80.66%
TIL Instil Bio	60.56%

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	5.30%
GRNA GreenLight Biosciences	30.30%
JNCE Jounce Therapeutics	6.92%
TIL Instil Bio	54.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	121	20.75 million	19.66 million	Optionable
GRNA GreenLight Biosciences	280	151.68 million	105.72 million	Not Optionable
JNCE Jounce Therapeutics	137	52.63 million	48.99 million	Optionable
TIL Instil Bio	49	6.50 million	2.95 million	Optionable

JNCE, ADVM, GRNA, and TIL Headlines

Source	Headline
	BiO-LiFE Herbalmeds Launches The Power of Sleep Campaign To Encourage Malaysians To Sleep Well and Stay Healthy finance.yahoo.com - May 1 at 9:06 AM
	Jentle Salon: BLACKPINK Jennie and Gentle Monster’s third collab will get a pop-up at MBS lifestyleasia.com - April 26 at 7:28 AM
	This actor once saw father saved murder accused, qualified for Olympics, then became Bollywood's top villain, died at... msn.com - April 21 at 9:58 AM
	Sustainability through global collaboration dailypioneer.com - April 19 at 7:54 PM
	Instil Bio (TIL) Price Target Decreased by 23.15% to 28.22 msn.com - April 17 at 12:21 PM
	Jefferies cuts Instil Bio to hold, cites drug discontinuation msn.com - April 12 at 1:45 PM
	Learning from nature, investing in people and ownership culture can future-proof the insight function research-live.com - March 29 at 7:34 AM
	What Makes Instil Bio (TIL) a New Buy Stock zacks.com - March 27 at 1:01 PM
	Instil Bio Non-GAAP EPS of -$1.26 beats by $2.14 seekingalpha.com - March 22 at 10:31 AM
	Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update globenewswire.com - March 21 at 5:00 PM
	UK Treasury to overhaul crypto regulations to strengthen AML measures forbesindia.com - March 14 at 7:37 AM
	A Very Private School — Charles Spencer’s privileged but painful education ft.com - March 12 at 9:18 AM
	Jon Cruddas: ‘Labour has to rediscover its moral purpose’ theguardian.com - March 11 at 2:59 PM
	Junglee Poker launches Apne Type Ke Log campaign featuring Anil Kapoor financialexpress.com - February 24 at 7:23 PM
	Instil Bio Stock (NASDAQ:TIL) Dividends: History, Yield and Dates benzinga.com - February 24 at 12:50 AM
	TIL therapies: the impact on cancer research labiotech.eu - February 22 at 2:43 PM
	Behind the new kind of cell therapy that just won FDA approval biopharmadive.com - February 22 at 8:26 AM
	Alexei Navalny death latest: Putin brings new criminal case against critic’s brother as mother pleads for body sg.yahoo.com - February 21 at 3:33 PM
	Alexei Navalny death latest: X restores wife Yulia’s account as Putin brings new case against critic’s brother independent.co.uk - February 20 at 11:59 PM
	How RSS textbooks are reshaping Indian history and science under Modi msn.com - February 19 at 9:49 AM
	Instil Bio Inc. thestreet.com - February 16 at 4:33 AM
	Boeing in ‘last chance saloon’, Emirates boss says msn.com - February 5 at 1:41 AM
	Auto industry stakeholders react to Interim Budget 2024 financialexpress.com - February 5 at 1:41 AM
	Interim Budget 2024: On path to a brighter and more prosperous India economictimes.indiatimes.com - February 2 at 7:52 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Adverum Biotechnologies

NASDAQ:ADVM

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

GreenLight Biosciences

NASDAQ:GRNA

FUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.

Jounce Therapeutics

NASDAQ:JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Instil Bio

NASDAQ:TIL

Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial